Sunesis Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sunesis Pharmaceuticals, Inc.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 10: Diversity, Equity And Inclusion
The acceleration of efforts to increase diversity among clinical trial subjects is expected to continue in 2023. Furthermore, many executives hope for greater inclusivity within companies, from new recruits to leadership.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
Deal Watch: BMS Returning IL-12 Candidate To Frequent Partner Dragonfly
The firms’ partnership goes back to pre-merger Celgene, and BMS still has Dragonfly candidates in its pipeline. Ji Xing gets hypertension candidate from Phase Bio.
Cardio Conversations: Steven Mickelsen Discusses PFA, Electrophysiology And What It Takes To Be A Physician Inventor
In the first episode of Medtech Insight’s new podcast series focused on cardiovascular technology, editor Reed Miller talks to Steven Mickelsen, one of the founders of Farapulse and Field Medical, about pulsed field ablation, an emerging technology that is changing electrophysiology.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.